No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study.
No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study.
复制标题
DOI：
10.2147/pgpm.s281645
复制
发表时间：
2021
影响因子：
1.9
通讯作者：
Olson JE
中科院分区：
文献类型：
--
作者：
Takahashi PY;Ryu E;Bielinski SJ;Hathcock M;Jenkins GD;Cerhan JR;Olson JE
药物基因组学数据在临床实践中的应用越来越多。然而，目前尚不清楚药物基因组学数据是否可以更广泛地用于预测住院或急诊科（艾德）就诊等结局。我们的目的是确定选定的药物基因组学表型和医院利用结果（住院和艾德就诊）之间的关联。该队列研究使用了来自马约诊所生物样本库的10，078例患者，采用RIGHT方案，对10种选定的药物基因（包括CYP 2D 6、CYP 2C 9、CYP 2C 19、CYP 3A 5、HLA B 5701、HLA B 5702、HLA B 5801、TPMT、SLCO 1B 1和DPYD）进行测序和解释表型。主要结局是住院，艾德访视作为次要结局。我们使用考克斯比例风险模型来检验每个药物基因组学表型与结局风险之间的关联。在随访期间（中位数[年] = 7.3），分别有13%（n=1354）和8%（n=813）的受试者经历住院和艾德访视。与未住院治疗的受试者相比，基线时住院患者年龄较大（中位年龄[岁]：67 vs 65），自评健康状况较差（一般/差：15% vs 4.7%），疾病负担较高（慢性疾病的中位数量：7 vs 4）。住院治疗与任何药物基因组学表型均无相关性。药物基因组学表型与疾病负担无关，疾病负担是医院利用结局的一个公认的风险因素。在随访期间，在艾德访视的患者中观察到相似的结果。在这个相对较大的生物样本库人群中，我们发现10种已确立的药物基因组学表型与住院或艾德访视无关，且与这些基因相关的特定药物使用无关。与药物基因组学信息相比，传统的住院风险因素如年龄和自评健康状况更有可能预测住院和/或艾德就诊。
The use of pharmacogenomics data is increasing in clinical practice. However, it is unknown if pharmacogenomics data can be used more broadly to predict outcomes like hospitalization or emergency department (ED) visit. We aim to determine the association between selected pharmacogenomics phenotypes and hospital utilization outcomes (hospitalization and ED visits). This cohort study utilized 10,078 patients from the Mayo Clinic Biobank in the RIGHT protocol with sequence and interpreted phenotypes for 10 selected pharmacogenes including CYP2D6, CYP2C9, CYP2C19, CYP3A5, HLA B 5701, HLA B 5702, HLA B 5801, TPMT, SLCO1B1, and DPYD. The primary outcome was hospitalization with ED visits as a secondary outcome. We used Cox proportional hazards model to test the association between each pharmacogenomics phenotype and the risk of the outcomes. During the follow-up period (median [in years] = 7.3), 13% (n=1354) and 8% (n=813) of the subjects experienced hospitalization and ED visits, respectively. Compared to subjects who did not experience hospitalization, hospitalized patients were older (median age [in years]: 67 vs 65), poorer self-rated health (15% vs 4.7% for fair/poor), and higher disease burden (median number of chronic conditions: 7 vs 4) at baseline. There was no association of hospitalization with any of the pharmacogenomics phenotypes. The pharmacogenomics phenotypes were not associated with disease burden, a well-established risk factor for hospital utilization outcomes. Similar findings were observed for patients with ED visits during the follow-up period. We found no association of 10 well-established pharmacogenomics phenotypes with either hospitalization or ED visits in this relatively large biobank population and outside the context of specific drug use related to these genes. Traditional risk factors for hospitalization like age and self-rated health were much more likely to predict hospitalization and/or ED visits than this pharmacogenomics information.
影响因子：
8.9
作者：
Takahashi PY;Ryu E;Olson JE;Anderson KS;Hathcock MA;Haas LR;Naessens JM;Pathak J;Bielinski SJ;Cerhan JR
通讯作者：
Cerhan JR